EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL‐15 Superagonist SHR‐1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment

Qian Zhang iD, Congli Hu, Minlin Jiang, Yuanyuan Wang, Heng Luo, Xuefei Li

The Clinical Respiratory Journal · 2025-08 · 19 (8)

DOI: 10.1111/crj.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 13.08.2025. Verfasst von Qian Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Lung Neoplasms, Interleukin-15, Carcinoma, Lewis Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin‐15 (IL‐15) is a pleiotropic cytokine recognized as a promising therapeutic agent in cancer immunotherapy. IL‐15 superagonists have shown efficacy across various cancers, yet their effects in lung cancer immunotherapy remain underexplored.

Methods

This study evaluated the antitumor effects of SHR‐1501 through intratumoral injection in two murine lung cancer models: Lewis lung carcinoma (LLC) and Kras G12D/p53−/− (KP). We employed flow cytometry to assess immune cell populations in the tumor microenvironment (TME) and systemic circulation. Immunohistochemistry (IHC) was used to analyze TME changes in tumor tissues, while single‐cell RNA sequencing provided insights into TME modulation following SHR‐1501 treatment. Additionally, we assessed the synergistic potential of combining SHR‐1501 with PD‐1 monoclonal antibody (mAb) therapy and explored the abscopal effect of SHR‐1501.

Results

SHR‐1501 significantly inhibited tumor growth in both KP and LLC models at 5 μg and 15 μg doses ( p = 0.0022 and p = 0.0002, respectively, for KP; p = 0.0508 and p = 0.0131, respectively, for LLC). Flow cytometry revealed increased infiltration of CD8+ T cells, effector memory CD8+ T cells (TEM), and natural killer (NK) cells in the TME. SHR‐1501 also enhanced systemic immune responses, increasing CD8+ T cells and TEM populations in peripheral blood and spleen, with an early NK cell elevation on day 7 post‐treatment. Single‐cell analysis indicated that SHR‐1501 promoted the activity of macrophages, increasing M1 macrophage proportions. Moreover, SHR‐1501 enhanced the antitumor immune response by promoting pro‐inflammatory changes across multiple cell types within the TME, including neutrophils, fibroblasts, and endothelial cells. When combined with PD‐1mAb, SHR‐1501 exhibited potent synergistic antitumor effects. The combination therapy significantly prolonged overall survival with no significant toxicity observed. Furthermore, SHR‐1501 may have the ability to induce an abscopal effect.

Conclusion

SHR‐1501 demonstrated potent antitumor activity, especially when combined with PD‐1 mAb. Its mechanism likely involves promoting CD8+ T cell and NK cell infiltration and enhancing M1 macrophage activity. These findings provide evidence for further clinical trials exploring SHR‐1501 in nonsmall cell lung cancer (NSCLC) therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentLung NeoplasmsInterleukin-15Carcinoma, Lewis LungAnimalsMiceMice, Inbred C57BLImmunotherapyDisease Models, AnimalCell Line, TumorKiller Cells, Natural

Stichwörter der Autor:innen

IL‐15 superagonistPD‐1/PD‐L1 inhibitorsSHR‐1501mouse modelnonsmall‐cell lung cancer

Substanzen

Interleukin-15

Autor:innen und Institutionen

  • Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Pharmacy, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

ORCID-Profile: Qian Zhang

Förderung

  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Q., Hu, C., Jiang, M., Wang, Y., Luo, H., & Li, X. (2025). IL‐15 Superagonist SHR‐1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment. The Clinical Respiratory Journal, 19(8). https://doi.org/10.1111/crj.70117

Vancouver

Zhang Q, Hu C, Jiang M, Wang Y, Luo H, Li X. IL‐15 Superagonist SHR‐1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment. The Clinical Respiratory Journal. 2025;19(8). doi:10.1111/crj.70117

BibTeX
@article{Zhang2025,
  author = {Zhang, Qian and Hu, Congli and Jiang, Minlin and Wang, Yuanyuan and Luo, Heng and Li, Xuefei},
  title = {IL‐15 Superagonist SHR‐1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment},
  journal = {The Clinical Respiratory Journal},
  year = {2025},
  volume = {19},
  number = {8},
  doi = {10.1111/crj.70117}
}
Kostenlos starten →